Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.

Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.

See below for some of our recent publications.

Donanemab (Kisunla; Eli Lilly and Co.) for Alzheimer Disease

Donanemab (Kisunla; Eli Lilly and Co.) is an intravenously administered amyloid beta-directed antibody indicated for the treatment of Alzheimer disease. Treatment with donanemab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease.